- Home
- FLUX vs CMMB Comparison
FLUX vs CMMB Comparison
Compare FLUX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- CMMB
- Stock Information
- Founded
- FLUX N/A
- CMMB 2004
- Country
- FLUX United States
- CMMB Israel
- Employees
- FLUX N/A
- CMMB N/A
- Industry
- FLUX Industrial Machinery/Components
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- FLUX Miscellaneous
- CMMB Health Care
- Exchange
- FLUX Nasdaq
- CMMB Nasdaq
- Market Cap
- FLUX 20.2M
- CMMB 23.6M
- IPO Year
- FLUX N/A
- CMMB N/A
- Fundamental
- Price
- FLUX $1.64
- CMMB $1.05
- Analyst Decision
- FLUX Strong Buy
- CMMB Strong Buy
- Analyst Count
- FLUX 3
- CMMB 2
- Target Price
- FLUX $6.33
- CMMB $9.00
- AVG Volume (30 Days)
- FLUX 85.0K
- CMMB 153.9K
- Earning Date
- FLUX 03-20-2025
- CMMB 03-03-2025
- Dividend Yield
- FLUX N/A
- CMMB N/A
- EPS Growth
- FLUX N/A
- CMMB N/A
- EPS
- FLUX N/A
- CMMB N/A
- Revenue
- FLUX $60,789,000.00
- CMMB N/A
- Revenue This Year
- FLUX $11.85
- CMMB N/A
- Revenue Next Year
- FLUX $13.10
- CMMB N/A
- P/E Ratio
- FLUX N/A
- CMMB N/A
- Revenue Growth
- FLUX N/A
- CMMB N/A
- 52 Week Low
- FLUX $1.15
- CMMB $0.58
- 52 Week High
- FLUX $5.46
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- FLUX 51.09
- CMMB 30.38
- Support Level
- FLUX $1.53
- CMMB $0.92
- Resistance Level
- FLUX $2.20
- CMMB $1.35
- Average True Range (ATR)
- FLUX 0.24
- CMMB 0.12
- MACD
- FLUX 0.03
- CMMB -0.01
- Stochastic Oscillator
- FLUX 47.05
- CMMB 24.78
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.